We focus on naturally occurring protective substances since they are more likely to be both safe and efficacious. Our primary products incorporate and emphasize the multifaceted “super antioxidant” compound, L-Ergothioneine (“ERGO”), as a key component. We own several patents and pending applications related to ERGO that cover current and planned products relevant to our nutraceutical and cosmecuetical businesses. Our patents and patent applications address ERGO’s protective effects and activities and the ERGO manufacturing process. Not stressing over their therapies.
Founded in 1965 and headquartered in Portland, OR, OXIS International, Inc is a provider of diagnosis and treatment services for oxidative stress-related diseases. Diagnostic assays and drug monitoring assays produced by its subsidiary, OXIS Health Products, make up the bulk of its sales. Its BXT-51072 product is currently undergoing trials, and is likely to treat inflammatory bowel disease.
In February 2006, it moved key administrative functions to its U.S. FDA certified cGMP device manufacturing facility in Foster City, CA This blog post deals about the oxidative stress discovered by OXIS International, Inc. is engaged in the research, development and sale of products that counteract the harmful effects of “oxidative stress.” Oxidative stress refers to the situations in which the body’s antioxidant and other defensive abilities to combat free radicals (a.k.a highly reactive species of oxygen and nitrogen) are overwhelmed and one’s normal healthy balance is either lost or severely compromised. Products include therapeutic nutraceutical products, cosmeceutical products and proprietary formulations and clinical products that are developed internally and/or out-licensed to biotech and pharmaceutical companies as drug candidates.
